Zacks Small Cap Research – WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones – Go Health Pro
By M. Marin NASDAQ:WINT Lead Drug Candidates, New Phase 2b Clinical Trial Data, Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company developing therapies for a range of cardiovascular and oncology treatments characterized by significant unmet need. The company’s lead indication area is cardiogenic … Read more
